Efficacy of TNF a blockade in cyclophosphamide resistant neuro-Behcet disease

被引:55
作者
Ribi, C [1 ]
Sztajzel, R
Delavelle, J
Chizzolini, C
机构
[1] Univ Hosp Geneva, Dept Internal Med, Geneva, Switzerland
[2] Univ Hosp Geneva, Dept Neurol, Geneva, Switzerland
[3] Univ Hosp Geneva, Dept Radiol, Geneva, Switzerland
关键词
D O I
10.1136/jnnp.2004.055434
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Behcet disease is a chronic relapsing inflammatory condition, predominantly affecting young adults, characterised by recurrent bipolar aphtae and systemic manifestations for which tumour necrosis factor (TNF) alpha blockade has recently emerged as an effective treatment. We report the case of a patient presenting with mucocutaneous and ocular manifestations who in the course of his disease developed CNS parenchymal involvement. While being treated with pulsed cyclophosphamide and corticosteroids, he suffered a relapse of his CNS involvement that was efficaciously controlled by infliximab. No disease activity was observed during a full year of TNF blockade, associated with azathioprine, colchicine, and corticosteroids. However, 7 months after the last administration of infliximab and still under immunosuppressant agents, CNS lesions recurred. Infliximab was successfully reintroduced and since continued with no side effects. The sequence of events observed in this patient suggests that TNF blockade is efficacious in suppressing neuro-Behcet disease and once introduced should be maintained for a prolonged period of time.
引用
收藏
页码:1733 / 1735
页数:3
相关论文
共 13 条
[1]
Mapping the HLA association in Behcet's disease - A role for tumor necrosis factor polymorphisms? [J].
Ahmad, T ;
Wallace, GR ;
James, T ;
Neville, M ;
Bunce, M ;
Mulcahy-Hawes, K ;
Armuzzi, A ;
Crawshaw, J ;
Fortune, F ;
Walton, R ;
Stanford, MR ;
Welsh, KI ;
Marshall, SE ;
Jewell, DP .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :807-813
[2]
Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease [J].
Evereklioglu, C ;
Er, H ;
Türköz, Y ;
Çekmen, M .
MEDIATORS OF INFLAMMATION, 2002, 11 (02) :87-93
[3]
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial [J].
Farrell, RJ ;
Alsahli, M ;
Jeen, YT ;
Falchuk, KR ;
Peppercorn, MA ;
Michetti, P .
GASTROENTEROLOGY, 2003, 124 (04) :917-924
[4]
Freysdottir J, 1999, CLIN EXP IMMUNOL, V118, P451
[5]
Neurological complications in Behcet's syndrome [J].
Kidd, D ;
Steuer, A ;
Denman, AM ;
Rudge, P .
BRAIN, 1999, 122 :2183-2194
[6]
Anti-tumour necrosis factor α monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome [J].
Licata, G ;
Pinto, A ;
Tuttolomondo, A ;
Banco, A ;
Ciccia, F ;
Ferrante, A ;
Triolo, G .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (03) :280-281
[7]
MEGE JL, 1993, J RHEUMATOL, V20, P1544
[8]
Robinson WH, 2001, ARTHRITIS RHEUM-US, V44, P1977, DOI 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO
[9]
2-6
[10]
Behcet's disease: a new target for anti-tumour necrosis factor treatment [J].
Sfikakis, PP .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 :51-53